Finance

Lists
Why is 300147 down 3,15%?
Dive Deeper
300147:SHE
Xiangxue Pharmaceutical Co Ltd
CN¥5,23
-3,15%
(-0,17) 1D
14 Okt., 15:04:31 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300147...
Open
CN¥5,40
High
CN¥5,45
Low
CN¥5,23
Mkt. cap
3,64 mjd
Avg. vol.
10,83 m
Volume
5,35 m
52-wk high
CN¥11,23
52-wk low
CN¥5,03
EPS
-CN¥2,16
Shares outstanding
661,28 m
No. of employees
3 k
Open
CN¥5,40
High
CN¥5,45
Low
CN¥5,23
Mkt. cap
3,64 mjd
Avg. vol.
10,83 m
Volume
5,35 m
52-wk high
CN¥11,23
52-wk low
CN¥5,03
EPS
-CN¥2,16
Shares outstanding
661,28 m
No. of employees
3 k
News stories
From web sources and news partners
Profile
Xiangxue Pharmaceutical Co., Ltd. also known as XPH, is a Chinese pharmaceutical company. It was headquartered in Guangzhou Economic and Technological Development Zone, Guangzhou, the capital of the Guangdong Province. The company started in a place that near to the tourist spot Luogang Xiangxue, thus called itself Xiangxue. Xiangxue Pharmaceutical was a constituent of SZSE 200 Index, but was removed in January 2017; it was inserted to SZSE 700 Index instead at the same time. SZSE 200, 300 and 700 Indexes are subsets of SZSE 1000 Index, the latter is a stock market index for the top 1,000 companies by free-float adjusted capitalization. In July 2017 Xiangxue was also removed from SZSE Component Index, an index for top 500 companies of the exchange. Wikipedia
About Xiangxue Pharmaceutical Co Ltd
CEO-
Employees2,66 k
Founded29 Des. 1997
Headquarters-
SectorPharmaceutical industry
Websitexphcn.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
327,92 m
449,49 m
354,16 m
348,62 m
Cost of goods sold
176,35 m
388,48 m
228,49 m
252,20 m
Cost of revenue
176,35 m
388,48 m
228,49 m
252,20 m
Research and development expenses
15,40 m
22,13 m
10,74 m
11,51 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
132,20 m
75,98 m
89,74 m
95,27 m
Operating expense
153,13 m
108,42 m
97,82 m
111,19 m
Total operating expenses
329,48 m
496,91 m
326,31 m
363,40 m
Operating income
-1,56 m
-47,41 m
27,85 m
-14,78 m
Other non operating income
302,00 k
-14,25 m
-944,82 k
-2,74 m
EBT including unusual items
-118,29 m
-1,00 mjd
-89,20 m
-147,88 m
EBT excluding unusual items
-67,96 m
-144,93 m
-40,82 m
-81,08 m
Income tax expense
3,13 m
30,08 m
9,14 m
5,48 m
Effective tax rate
-2,65%
-3,00%
-10,25%
-3,70%
Other operating expenses
3,55 m
4,05 m
-3,18 m
-1,15 m
Net income
-128,03 m
-1,03 mjd
-111,44 m
-157,38 m
Net profit margin
-39,04%
-229,21%
-31,47%
-45,14%
Earnings per share
-
-
-
-
Interest and investment income
-
175,82 k
23,18 k
15,53 k
Interest expense
-66,70 m
-83,47 m
-67,75 m
-63,58 m
Net interest expenses
-66,70 m
-83,30 m
-67,73 m
-63,56 m
Depreciation and amortization charges
-
-
-
-
EBITDA
52,99 m
15,22 k
75,28 m
37,21 m
Gain or loss from assets sale
932,06 k
-8,92 m
-
-107,04 k
AI content may include mistakes. Learn more
Google-programme